Educational reference only. Not medical advice. Nothing on this site is for sale.
Latest
CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyTrial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialFDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesCompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeTrial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMTrial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetTrial resultFull TRIUMPH-2 retatrutide results published in The LancetFDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesWADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances
Sign in

Bone & mineral

Abaloparatide

Also called Tymlos, Eladynos, BA058, BIM-44058

Abaloparatide is a lab-made peptide modeled on parathyroid hormone-related protein (PTHrP). Like teriparatide, it is a daily injection that builds new bone, and it is FDA-approved for osteoporosis in women and men at high fracture risk.

FDA-approvedApproved by the FDA for at least one use after large human trials.

All printable flashcards

Drawn from its published sequence: 34 residues, one bead each.

Overview

Abaloparatide is a lab-made peptide modeled on parathyroid hormone-related protein (PTHrP). Like teriparatide, it is a daily injection that builds new bone, and it is FDA-approved for osteoporosis in women and men at high fracture risk.

How it works

Established: abaloparatide activates the PTH1 receptor and its cAMP signaling pathway. Daily pulsed dosing stimulates osteoblasts to lay down new bone on both inner (trabecular) and outer (cortical) bone surfaces (FDA label). Proposed: it may favor a receptor conformation that gives a shorter signal than teriparatide, which has been suggested to explain less calcium rise, but this is not established in the label.

What research shows

  • 18-month RCT in postmenopausal women (824 abaloparatide vs 821 placebo): new vertebral fractures 0.6% vs 4.2%, an 86% relative reduction (FDA label, Study 003).
  • 12-month RCT in men (149 vs 79): lumbar spine BMD +8.5% vs +1.2%, total hip +2.1% vs <0.1% (FDA label, Study 019).
  • Rats given abaloparatide developed osteosarcoma in a dose- and time-dependent way; whether this applies to humans is unknown (FDA label).

Doses studied in people

Study or labelDose usedSource
FDA label (Tymlos), postmenopausal women and men with osteoporosis80 mcg subcutaneously once daily1

Label dose is 80 mcg once daily; total lifetime use beyond 2 years is not recommended because longer use has not been studied.

Read this first: these are the amounts given to participants in published studies or written on official prescribing labels, reported for reference. They are not recommendations. Trial doses were chosen for specific patients under medical supervision, and a dose that is safe in one person can be harmful in another.

Weekly protocol

How the schedule looks week by week. Each chart says where it comes from: a prescribing label, a clinical trial, or a protocol commonly reported online.

Tymlos label dosing

Prescribing label

One week

D1D2D3D4D5D6D7

Once daily · Subcutaneous injection

Dose by week

80 mcgwk 1+
Course
Up to 2 years in a lifetime
Note
Cumulative use beyond 2 years is not recommended.
Source
TYMLOS (abaloparatide) injection prescribing information (FDA, 2026)

Reference only, not a recommendation. Label and trial schedules were set for specific patients under medical supervision. Use the calculator only to understand the arithmetic.

Safety

  • Orthostatic hypotension, usually within 4 hours of injection; first doses should be given where the patient can sit or lie down (FDA label).
  • Hypercalcemia and hypercalciuria/kidney stones; not recommended with hypercalcemic disorders (FDA label).
  • Osteosarcoma seen in rats; avoid in people at higher risk (open growth plates, Paget's disease, skeletal cancer, prior skeletal radiation) (FDA label).
  • Common reactions in women vs placebo: hypercalciuria 11% vs 9%, dizziness 10% vs 6%, nausea 8% vs 3%, palpitations 5% vs 0.4% (FDA label).
  • Hypersensitivity, including anaphylaxis and angioedema (FDA label).

Report side effects of any drug or product to the FDA through MedWatch. For a possible poisoning in the US, call Poison Control at 1-800-222-1222.

Storage and stability

Before first use, refrigerate at 2-8°C; after first use, may be kept at 20-25°C for up to 30 days; do not freeze (FDA label).

General lab handling, not instructions for personal use. See Storage and stability.

History

Abaloparatide was invented at Ipsen (BIM-44058) and developed by Radius Health as BA058. The FDA approved it as Tymlos in April 2017 for postmenopausal osteoporosis; the EU approved it (Eladynos) in December 2022. The FDA removed its osteosarcoma boxed warning around December 2021 based on long-term PTH-class data, and later expanded the label to men with osteoporosis.

Common questions

Is abaloparatide FDA-approved?

Yes. It was approved as Tymlos in 2017 for postmenopausal osteoporosis, and the label was later expanded to men 13. The EU approved it as Eladynos in December 2022 3.

What does the research show?

In an 18-month trial, new spine fractures occurred in 0.6% of women on abaloparatide vs 4.2% on placebo 1. In a 12-month trial in men, spine bone density rose 8.5% vs 1.2% 1.

What dose is on the FDA label?

The label lists 80 mcg injected under the skin once daily 1. Lifetime use beyond 2 years is not recommended because it has not been studied 1. This is label information, not advice.

Does abaloparatide still carry a cancer warning?

Rats developed osteosarcoma, a bone cancer, and whether this applies to people is unknown 1. The FDA removed the boxed warning around December 2021 2.

What are the common side effects?

In women, high urine calcium affected 11% vs 9% on placebo, dizziness 10% vs 6%, nausea 8% vs 3% and palpitations 5% vs 0.4% 1. A drop in blood pressure on standing can occur within 4 hours of a dose 1.

How is abaloparatide stored?

It is refrigerated before first use, then may be kept at 20 to 25°C for up to 30 days, and must not be frozen 1.

Related compounds

Bone & mineralFDA-approvedFlashcard

Teriparatide

Forteo · rhPTH(1-34)

Teriparatide is a lab-made copy of the first 34 amino acids of human parathyroid hormone.

Bone & mineralFDA-approvedFlashcard

Calcitonin (salmon)

Miacalcin · salmon calcitonin

Salmon calcitonin is a thyroid-type hormone taken from salmon that lowers blood calcium and slows bone breakdown.

Sources

  1. TYMLOS (abaloparatide) injection prescribing information FDA label
  2. FDA approves removal of boxed warning from label for osteoporosis drug Tymlos Journal
  3. Abaloparatide (Wikipedia; sequence, CAS, approval history) Journal
  4. WADA 2026 Prohibited List Regulatory

Last reviewed 2026-10-25 · How we research · Found an error? See our corrections policy.